No biomarker

News alerts, weekly reports and conference planners

No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	darolutamide Sensitive: A1 - Approval PharmiWeb - 1 week (New A2) darolutamide Sensitive : A1 PharmiWeb - 1wk	darolutamide Sensitive: A1 - Approval PharmiWeb - 1 week darolutamide Sensitive : A1 PharmiWeb - 1 week - (New A2)
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	epcoritamab Sensitive: A1 - Approval FDA - 1 week (New A1) epcoritamab Sensitive : A1 FDA - 1wk	epcoritamab Sensitive: A1 - Approval FDA - 1 week epcoritamab Sensitive : A1 FDA - 1 week - (New A1)
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	IMPT-314 Sensitive: B - Late Trials PRNewswire - 1 week (New B) IMPT-314 Sensitive : B PRNewswire - 1wk	IMPT-314 Sensitive: B - Late Trials PRNewswire - 1 week IMPT-314 Sensitive : B PRNewswire - 1 week - (New B)
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	IMPT-314 Sensitive: B - Late Trials PRNewswire - 1 week (New B) IMPT-314 Sensitive : B PRNewswire - 1wk	IMPT-314 Sensitive: B - Late Trials PRNewswire - 1 week IMPT-314 Sensitive : B PRNewswire - 1 week - (New B)
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	venetoclax + obinutuzumab Sensitive: A1 - Approval N Engl J Med - 2 weeks (New B) venetoclax + obinutuzumab Sensitive : A1 N Engl J Med - 2wk	venetoclax + obinutuzumab Sensitive: A1 - Approval N Engl J Med - 2 weeks venetoclax + obinutuzumab Sensitive : A1 N Engl J Med - 2 weeks - (New B)
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	isatuximab-irfc Sensitive: A1 - Approval Blood Cancer J - 2 weeks (New B) isatuximab-irfc Sensitive : A1 Blood Cancer J - 2wk	isatuximab-irfc Sensitive: A1 - Approval Blood Cancer J - 2 weeks isatuximab-irfc Sensitive : A1 Blood Cancer J - 2 weeks - (New B)
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	rituximab + zanubrutinib Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) rituximab + zanubrutinib Sensitive : A2 NCCN - 2wk	rituximab + zanubrutinib Sensitive: A2 - Guideline NCCN - 2 weeks rituximab + zanubrutinib Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	rituximab + acalabrutinib Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) rituximab + acalabrutinib Sensitive : A2 NCCN - 2wk	rituximab + acalabrutinib Sensitive: A2 - Guideline NCCN - 2 weeks rituximab + acalabrutinib Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	R-Maxi-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) R-Maxi-CHOP Sensitive : A2 NCCN - 2wk	R-Maxi-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks R-Maxi-CHOP Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	R-DHAP + R-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) R-DHAP + R-CHOP Sensitive : A2 NCCN - 2wk	R-DHAP + R-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks R-DHAP + R-CHOP Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	R-DHAX + R-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) R-DHAX + R-CHOP Sensitive : A2 NCCN - 2wk	R-DHAX + R-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks R-DHAX + R-CHOP Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	R-DHAC + R-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) R-DHAC + R-CHOP Sensitive : A2 NCCN - 2wk	R-DHAC + R-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks R-DHAC + R-CHOP Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + ipilimumab + cabozantinib tablet Sensitive: B - Late Trials N Engl J Med - 2 weeks (New B) nivolumab + ipilimumab + cabozantinib tablet Sensitive : B N Engl J Med - 2wk	nivolumab + ipilimumab + cabozantinib tablet Sensitive: B - Late Trials N Engl J Med - 2 weeks nivolumab + ipilimumab + cabozantinib tablet Sensitive : B N Engl J Med - 2 weeks - (New B)
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	ACR-368 Sensitive: B - Late Trials GlobeNewswire - 2 weeks (New B) ACR-368 Sensitive : B GlobeNewswire - 2wk	ACR-368 Sensitive: B - Late Trials GlobeNewswire - 2 weeks ACR-368 Sensitive : B GlobeNewswire - 2 weeks - (New B)
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	ACR-368 Sensitive: B - Late Trials GlobeNewswire - 2 weeks (New B) ACR-368 Sensitive : B GlobeNewswire - 2wk	ACR-368 Sensitive: B - Late Trials GlobeNewswire - 2 weeks ACR-368 Sensitive : B GlobeNewswire - 2 weeks - (New B)
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks (New A1) lisocabtagene maraleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3wk	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks lisocabtagene maraleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3 weeks - (New A1)
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks (New A1) lisocabtagene maraleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3wk	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks lisocabtagene maraleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3 weeks - (New A1)
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks (New A1) lisocabtagene maraleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3wk	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks lisocabtagene maraleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3 weeks - (New A1)
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	FOLFIRI Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) FOLFIRI Sensitive : A2 NCCN - 3wk	FOLFIRI Sensitive: A2 - Guideline NCCN - 3 weeks FOLFIRI Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	OFF Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) OFF Sensitive : A2 NCCN - 3wk	OFF Sensitive: A2 - Guideline NCCN - 3 weeks OFF Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
No biomarker	Gastric Adenocarcinoma	No biomarker	Gastric Adenocarcinoma	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive : A1	docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	carfilzomib Sensitive: A1 - Approval carfilzomib Sensitive : A1	carfilzomib Sensitive: A1 - Approval carfilzomib Sensitive : A1
No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A1 - Approval cabozantinib capsule Sensitive : A1	cabozantinib capsule Sensitive: A1 - Approval cabozantinib capsule Sensitive : A1

No biomarker

Associations